Dheyriat L, Ward D, Beaugerie L, Jess T, Kirchgesner J. Risk of recurrent acute arterial events associated with thiopurines and anti-tumor necrosis factor in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2023 Jan;21(1):164-172.e. doi: 10.1016/j.cgh.2022.06.011
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021 Nov 20. doi: 10.1016/j.cgh.2021.11.020
Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale MK. Factors related to the use of topical vs. oral NSAIDs for sprains, strains, and contusions in a senior population: a retrospective analysis of administrative claims data. Drugs Aging. 2018 Oct;35(10):937-50. doi: 10.1007/s40266-018-0585-8
McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056
Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6
Layton JB, Klemmer PJ, Christiansen CF, Bomback AS, Baron JA, Sandler RS, Kshirsagar AV. Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1514-21. doi: 10.1016/j.cgh.2014.01.034
Lukert B, Satram-Hoang S, Wade S, Anthony MS, Gao G, Downs R. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study. Drugs Aging. 2011 Sep 1;28(9):713-27.
Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-65.
Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, Engel LS. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159. doi: 10.1016/j.cgh.2007.05.022
Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007 May 1;5(5):534-40.